Bioequivalence of the BI 1015550 High Dose Formulation C2 and the BI 1015550 High Dose Formulation C1 (Phase 3 Formulation) Following Oral Administration in Healthy Subjects (an Open-label, Randomised, Single-dose, Two-way Crossover Trial)
Latest Information Update: 02 Jun 2025
At a glance
- Drugs Nerandomilast (Primary)
- Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 19 Sep 2024 Status changed from recruiting to completed.
- 23 Aug 2024 Planned End Date changed from 1 Sep 2024 to 6 Sep 2024.
- 23 Aug 2024 Planned primary completion date changed from 1 Sep 2024 to 6 Sep 2024.